Interferon alfa-2a biosimilar (Blau Pharmaceuticals)

干扰素α-2a生物类似药 (Blau Pharmaceuticals)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon alfa-2a biosimilar (Blau Pharmaceuticals)
Drug Alias Name干扰素α-2a生物仿制药 (Blau Pharmaceuticals)recombinant interferon alpha-2aBLAUFERON-A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellHepatitis C +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBlau Farmaceutica Sa
China Registration ClassN/A

Develop Information

Active CompaniesBlau Farmaceutica Sa
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellHepatitis C +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB04
Related LinksN/A